Vertex Pharmaceuticals (VRTX)

Here's how I'm staying calm as valuations hit record highs.

The company's gene-editing-focused platform looks promising.

Vertex is expanding beyond its cystic fibrosis franchise.

Vertex Pharmaceuticals (NASDAQ:VRTX) outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept in IgA nephropathy and inaxaplin in APOL1-mediated kidney disease, or AMKD. Chief Executive Officer and President Reshm

AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with concentrated cystic fibrosis exposure.

Buffett has warned about "gambling" in the market.

The company's expertise in gene editing could lead to more breakthroughs.

Billionaire investor Cathie Wood, through her ARK ETFs, made big buys of CRISPR Therapeutics on Friday, Oct. 9, and Monday, Oct. 12.

The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like ...

Vertex Pharmaceuticals is showing that it isn't a one-trick pony.

Vertex raised its full-year outlook in Q2 with a growing pipeline across multiple disease areas. Moderna’s mRNA flu vaccine just cleared a key FDA hurdle with an expanding oncology pipeline behind it.

“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ...

Most of any gains (or lack thereof) from here will be driven by just three factors.

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on hi...

One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability or growth potential.

Vertex dominates cystic fibrosis with expanding disease coverage and a pipeline entering new therapeutic areas. Axsome is building a commercial drug portfolio quickly but is still working toward consistent profitability.

This biotech player is firing on all cylinders.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry...

And there could be more positive developments ahead.

One is burning cash while chasing gene-editing breakthroughs. The other generates billions from a single therapy. Their divergent paths reveal starkly different risk-reward profiles.

Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.

This company has had plenty of setbacks in recent years, but it generally bounces back.

Vertex Pharmaceuticals has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 13....

With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for investors without being a smooth ride.